100 related articles for article (PubMed ID: 1279215)
1. Idiopathic resistance to luteinizing hormone-releasing hormone analogue in a patient with prostatic carcinoma.
Jorion JL
J Urol; 1992 Nov; 148(5):1539-40. PubMed ID: 1279215
[No Abstract] [Full Text] [Related]
2. Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Schulze H; Senge T
J Urol; 1990 Oct; 144(4):934-41. PubMed ID: 2144596
[TBL] [Abstract][Full Text] [Related]
3. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
4. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
[TBL] [Abstract][Full Text] [Related]
5. [Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements].
Bantis A; Zissimopoulos A; Athanasiadou P; Gonidi M; Agelonidou E; Strataki A; Matthaios D; Tsartsarakis A
Hell J Nucl Med; 2007; 10(1):56-61. PubMed ID: 17450256
[TBL] [Abstract][Full Text] [Related]
6. Prostatic cancer: treatment with long-acting LHRH analogue.
Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
[TBL] [Abstract][Full Text] [Related]
7. Prolonged hypogonadism after pulsed gonadotropin-releasing hormone agonist for prostate cancer.
Stevens MJ; Bell DR; Blome SA; Begbie SD
Lancet; 1994 Jul; 344(8917):274-5. PubMed ID: 7913195
[No Abstract] [Full Text] [Related]
8. Resistance to gonadotropin-releasing hormone agonist in a patient with metastatic prostate cancer.
Krongrad A; Brady J; Rodriguez RJ
South Med J; 1997 Apr; 90(4):460-1. PubMed ID: 9114847
[No Abstract] [Full Text] [Related]
9. Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol.
Bruchovsky N; Goldenberg SL; Akakura K; Rennie PS
Cancer; 1993 Sep; 72(5):1685-91. PubMed ID: 7688656
[TBL] [Abstract][Full Text] [Related]
10. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
[TBL] [Abstract][Full Text] [Related]
11. Prostate carcinoma with peripheral metastases after prostatectomy and low levels of serum prostate specific antigen.
Seven B; Varoglu E; Cayir K; Sahin A; Kantarci M
Hell J Nucl Med; 2008; 11(1):53-4. PubMed ID: 18392233
[No Abstract] [Full Text] [Related]
12. A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Chen Y; Kolvenbag GJ
Cancer; 1996 Nov; 78(10):2164-9. PubMed ID: 8918410
[TBL] [Abstract][Full Text] [Related]
13. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
Bélanger A; Labrie F; Dupont A; Brochu M; Cusan L
Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
[TBL] [Abstract][Full Text] [Related]
15. Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Spitz IM; Chertin B; Fridmans A; Farkas A; Belanger A; Hartman H; Labrie F
Prostate Cancer Prostatic Dis; 2009; 12(1):100-3. PubMed ID: 18574491
[TBL] [Abstract][Full Text] [Related]
16. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
Spitz IM; Chertin B; Lindenberg T; Farkas A
N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
[No Abstract] [Full Text] [Related]
17. The efficacy and safety of degarelix, a GnRH antagonist: a 12-month, multicentre, randomized, maintenance dose-finding phase II study in Japanese patients with prostate cancer.
Ozono S; Ueda T; Hoshi S; Yamaguchi A; Maeda H; Fukuyama Y; Takeda K; Ohashi Y; Tsukamoto T; Naito S; Akaza H
Jpn J Clin Oncol; 2012 Jun; 42(6):477-84. PubMed ID: 22457321
[TBL] [Abstract][Full Text] [Related]
18. [Lack of effect of therapy with LHRH analogs, alone or associated with flutamide, on prolactin levels in advanced prostatic carcinoma].
Banchini A; Zavaroni D; Tarditi E; Cortellini P; Ziveri M; Polotti R; Stefani F; Valenti G
Minerva Endocrinol; 1989; 14(3):165-8. PubMed ID: 2533662
[TBL] [Abstract][Full Text] [Related]
19. Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Kinouchi T; Maeda O; Ono Y; Meguro N; Kuroda M; Usami M
Int J Urol; 2002 Jun; 9(6):359-61. PubMed ID: 12110102
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous 17 beta-estradiol in treatment of cancer of prostate.
Steg A; Benoit G
Urology; 1979 Oct; 14(4):373-5. PubMed ID: 227153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
